Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark P Lythgoe

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Lancet Regional Health. Americas|February 13, 2023
CostPlus and implications for generic imatinibKristina Jenei, Mark P Lythgoe, Vinay Prasad
Journal of the American Geriatrics Society|June 6, 2022
General payments from Biogen to U.S. physicians between 2015 and 2020Kristina Jenei, Mark P Lythgoe, Vinay Prasad
JAMA Oncology|July 8, 2021
The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated ApprovalKerrington Powell, Mark P Lythgoe, Vinay Prasad
BMJ (Clinical Research Ed.)|January 29, 2022
Regulatory decisions diverge over aducanumab for Alzheimer's diseaseMark P Lythgoe, Kristina Jenei, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|November 4, 2021
The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapyMark P Lythgoe, Timothée Olivier, Vinay Prasad
BMJ Open Gastroenterology|October 22, 2021
Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studiesPaul Middleton, Catherine Hsu, Mark P Lythgoe
BJU International|March 6, 2023
Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinomaDavid J Benjamin, Mark P Lythgoe, Arash Rezazadeh
The Lancet. Oncology|January 5, 2024
Shortages of essential cancer medicines: who is responsible and what are the possible solutions?Kristina Jenei, Mark P Lythgoe, Kerstin N Vokinger
Expert Opinion on Pharmacotherapy|October 8, 2020
Advances in cyclin-dependent kinase inhibitors for the treatment of melanomaMaximilian Julve, James J Clark, Mark P Lythgoe
Journal of Cancer Policy|January 13, 2023
Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?Ali Raza Khaki, Mark P Lythgoe, Vinay Prasad
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Lancet Regional Health. Americas|February 13, 2023
CostPlus and implications for generic imatinibKristina Jenei, Mark P Lythgoe, Vinay Prasad
Journal of the American Geriatrics Society|June 6, 2022
General payments from Biogen to U.S. physicians between 2015 and 2020Kristina Jenei, Mark P Lythgoe, Vinay Prasad
JAMA Oncology|July 8, 2021
The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated ApprovalKerrington Powell, Mark P Lythgoe, Vinay Prasad
BMJ (Clinical Research Ed.)|January 29, 2022
Regulatory decisions diverge over aducanumab for Alzheimer's diseaseMark P Lythgoe, Kristina Jenei, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|November 4, 2021
The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapyMark P Lythgoe, Timothée Olivier, Vinay Prasad
BMJ Open Gastroenterology|October 22, 2021
Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studiesPaul Middleton, Catherine Hsu, Mark P Lythgoe
BJU International|March 6, 2023
Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinomaDavid J Benjamin, Mark P Lythgoe, Arash Rezazadeh
The Lancet. Oncology|January 5, 2024
Shortages of essential cancer medicines: who is responsible and what are the possible solutions?Kristina Jenei, Mark P Lythgoe, Kerstin N Vokinger
Expert Opinion on Pharmacotherapy|October 8, 2020
Advances in cyclin-dependent kinase inhibitors for the treatment of melanomaMaximilian Julve, James J Clark, Mark P Lythgoe
Journal of Cancer Policy|January 13, 2023
Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?Ali Raza Khaki, Mark P Lythgoe, Vinay Prasad
Pageof 7